355 related articles for article (PubMed ID: 33127846)
1. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
[TBL] [Abstract][Full Text] [Related]
2. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
[TBL] [Abstract][Full Text] [Related]
3. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
[TBL] [Abstract][Full Text] [Related]
5. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
8. HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis.
Yu S; Zhao Z; Chen L; Gu T; Yu H; Tang H; Wang Q; Wu Y
Immunotherapy; 2021 Feb; 13(3):195-200. PubMed ID: 33238795
[TBL] [Abstract][Full Text] [Related]
9. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
Scobie MR; Zhou KI; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
[TBL] [Abstract][Full Text] [Related]
10. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
11. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
Morris LGT
Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
13. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
Nassar AH; Adib E; Abou Alaiwi S; El Zarif T; Groha S; Akl EW; Nuzzo PV; Mouhieddine TH; Perea-Chamblee T; Taraszka K; El-Khoury H; Labban M; Fong C; Arora KS; Labaki C; Xu W; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Zaitlen N; Schoenfeld AJ; Schultz N; Berger MF; MacConaill LE; Ananda G; Kwiatkowski DJ; Choueiri TK; Schrag D; Carrot-Zhang J; Gusev A
Cancer Cell; 2022 Oct; 40(10):1161-1172.e5. PubMed ID: 36179682
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.
Scott SC; Shao XM; Niknafs N; Balan A; Pereira G; Marrone KA; Lam VK; Murray JC; Feliciano JL; Levy BP; Ettinger DS; Hann CL; Brahmer JR; Forde PM; Karchin R; Naidoo J; Anagnostou V
Front Oncol; 2022; 12():945798. PubMed ID: 35992816
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
17. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
19. An
Lin J; Liu J; Hao SG; Lan B; Zheng XB; Xiong JN; Zhang YQ; Gao X; Chen CB; Chen L; Huang YF; Luo H; Yi YT; Yi X; Lu JP; Zheng XW; Chen G; Wang XF; Chen Y
Front Immunol; 2022; 13():1022598. PubMed ID: 36505399
[TBL] [Abstract][Full Text] [Related]
20. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
